Susquehanna International Group, LLP Acelrx Pharmaceuticals Inc Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

17 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 16, 2022	SELL	$0.28 - $0.61 $17,416 - $37,942	-62,200 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$0.49 - $1.02 $61,054 - $127,092	-124,600 Reduced 66.7%	62,200 $35,000
Q3 2021 Nov 15, 2021	BUY	$0.93 - $1.51 $69,750 - $113,250	75,000 Added 67.08%	186,800 $191,000
Q2 2021 Aug 11, 2021	SELL	$1.03 - $1.7 $110,210 - $181,900	-107,000 Reduced 48.9%	111,800 $154,000
Q1 2021 May 17, 2021	BUY	$1.25 - $2.77 $123,875 - $274,507	99,100 Added 82.79%	218,800 $372,000
Q4 2020 Feb 16, 2021	BUY	$1.18 - $1.98 $62,304 - $104,544	52,800 Added 78.92%	119,700 $148,000
Q3 2020 Nov 16, 2020	SELL	$1.01 - $1.81 $16,059 - $28,779	-15,900 Reduced 19.2%	66,900 $95,000
Q4 2019 Feb 14, 2020	SELL	$1.66 - $2.4 $25,066 - $36,240	-15,100 Reduced 15.42%	82,800 $175,000
Q3 2019 Nov 14, 2019	SELL	$2.1 - $2.87 $72,450 - $99,015	-34,500 Reduced 26.06%	97,900 $215,000
Q2 2019 Aug 14, 2019	SELL	$2.1 - $3.93 $284,550 - $532,515	-135,500 Reduced 50.58%	132,400 $335,000
Q1 2019 May 15, 2019	BUY	$2.35 - $3.83 $227,010 - $369,978	96,600 Added 56.39%	267,900 $932,000
Q4 2018 Feb 14, 2019	BUY	$2.13 - $4.8 $154,851 - $348,960	72,700 Added 73.73%	171,300 $396,000
Q3 2018 Nov 14, 2018	BUY	$2.6 - $4.6 $45,240 - $80,040	17,400 Added 21.43%	98,600 $380,000
Q2 2018 Aug 14, 2018	BUY	$2.13 - $4.2 $9,798 - $19,320	4,600 Added 6.01%	81,200 $274,000
Q1 2018 May 15, 2018	SELL	$1.7 - $2.35 $18,700 - $25,850	-11,000 Reduced 12.56%	76,600 $161,000
Q4 2017 Feb 14, 2018	SELL	$1.75 - $5.5 $188,475 - $592,350	-107,700 Reduced 55.15%	87,600 $177,000
Q3 2017 Nov 14, 2017	BUY	$2.9 - $4.6 $566,370 - $898,379	195,300	195,300 $898,000

About ACELRX PHARMACEUTICALS INC

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

More about ACRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account